BPC-157
Synthetic pentadecapeptide
A 15-amino-acid synthetic peptide fragment studied for its purported role in tissue-repair research.
Overview
BPC-157 is a synthetic peptide whose sequence corresponds to a partial fragment of human body protection compound (BPC), a protein reported to be present in gastric juice. It does not occur naturally as an isolated peptide and is produced synthetically for research.
At a glance
What BPC-157 does
BPC-157 is a synthetic 15-amino-acid sequence derived from a protein found in human gastric juice, and the bulk of what is known about it comes from cytoprotection and tissue-repair studies. In these preclinical models it acts primarily as an angiogenic and cytoprotective agent: it promotes the formation of new blood vessels at injury sites, stabilizes existing endothelium, and speeds the migration and proliferation of the fibroblasts and tenocytes that rebuild connective tissue. Rather than a single receptor, it appears to work by nudging several repair-related pathways at once.
Mechanistically, animal and cell-culture work implicates upregulation of VEGF receptor 2 (VEGFR2) signaling and activation of the Akt-eNOS axis, which together drive angiogenesis and increase local nitric oxide availability. BPC-157 also modulates the nitric oxide system more broadly, interacts with growth-factor signaling (including reported effects on the FAK-paxillin pathway that governs cell migration), and has been described as influencing dopaminergic, serotonergic, and prostaglandin systems in ways that may explain its gastroprotective and analgesic observations. In gut models it protects the mucosa and helps maintain vascular integrity after injury.
The evidence base is almost entirely preclinical: rats and mice, plus in-vitro endothelial and fibroblast assays. Reported outcomes include faster tendon, ligament, muscle, and gut-lining healing with improved collagen organization and biomechanical strength. There are essentially no rigorous published human clinical trials, so while the animal literature is unusually broad and consistent, its translation to people remains unproven.
Effects reported in research
- Accelerated healing of transected Achilles tendon in rat models, with improved collagen organization and greater biomechanical (tensile) strength (animal only).
- Increased angiogenesis at injury sites via upregulation of VEGFR2 signaling and the Akt-eNOS pathway (animal and in-vitro).
- Enhanced fibroblast and tenocyte migration and proliferation, partly through FAK-paxillin signaling, promoting connective-tissue repair (in-vitro).
- Gastric and intestinal mucosal cytoprotection, reducing ulceration and preserving vascular integrity after chemical or ischemic injury (animal).
- Improved recovery in muscle-crush and ligament-injury models, with faster functional recovery (animal only).
- Modulation of the nitric oxide system, counteracting damage from NO-blockade in vascular injury models (animal).
- Analgesic effects in nerve-injury and pain models, associated with nerve-repair signaling (animal only).
- No published rigorous human clinical trial data confirms these effects; the entire efficacy picture is preclinical.
Effects listed reflect findings reported in the research literature — many in animal or in-vitro models. Listing an effect is not a claim of efficacy or a therapeutic indication in humans.
Mechanism of action
In animal and in-vitro studies, BPC-157 has been associated with promotion of angiogenesis and modulation of growth-factor signaling pathways, including effects reported on the VEGFR2 pathway and nitric oxide systems. Researchers have also described interactions with the FAK-paxillin pathway and effects on fibroblast and tendon-cell migration. These mechanisms are characterized primarily in rodent models and cell culture and have not been established in controlled human trials.
Mechanistic description reflects published research-literature understanding. Much peptide research is preclinical (in-vitro or animal-model); mechanism in humans may differ and is not established for many compounds.
What it's studied for
Research contexts in which BPC-157 appears in the literature. Listing a research area is not a claim of efficacy or a therapeutic indication.
Key characteristics
- A 15-amino-acid synthetic peptide derived from a fragment of a gastric protein sequence
- Most published evidence comes from rodent and in-vitro studies rather than human clinical trials
- Frequently studied in models of connective-tissue and gastrointestinal injury
- Reported to be relatively stable in gastric juice in preclinical work
- Not an approved drug in any major jurisdiction
Reported research dosing reference only
Educational reference, not dosing guidance. The figures below summarize amounts reported in published research and research-community protocols, provided for educational and research context only. They are not medical advice, not a recommendation, and not instructions for human use. BPC-157 is a research compound.
In rodent studies BPC-157 is most commonly administered intramuscularly or intraperitoneally at microgram-per-kilogram doses. These are experimental animal figures reported in the research literature, provided for research context only and not as dosing guidance for humans.
- Rodent studies: intramuscular doses commonly reported around 20, 100, and 500 mcg/kg (dose-ranging)
- Widely-referenced research-summary figures for reconstituted material: on the order of ~200-500 mcg/day (reference figure only)
Elimination half-life reported under ~30 minutes with a documented PK/PD disconnect (effects outlast plasma presence). Bioavailability after IM injection reported ~14-19% in rats and ~45-51% in dogs. Not an approved drug; figures are research-reference only.
How it compares
Unlike copper-binding cosmetic tripeptides or the actin-modulating TB-500, BPC-157 is a longer synthetic peptide studied primarily for connective-tissue and gastrointestinal repair endpoints in animals.
Commonly studied alongside
Compounds frequently researched together with BPC-157 in the literature. Cross-referenced for research context — not a usage or combination recommendation.
Handling & Stability
Lyophilized peptides are stored cold, protected from light, and reconstituted only at the time of intended in-vitro work.
- Avoid repeated freeze-thaw cycles
- Verify supplier lot and Certificate of Analysis
- Follow institutional lab-safety protocols
Analytical & COA Concepts
Reputable research suppliers publish a third-party Certificate of Analysis per batch. Key analytical concepts referenced in COAs include:
Category Context
BPC-157 sits in the Healing & Recovery area of the PeptiDex library.
- Entry type: Research compound reference
- Browse the full library →
- Glossary of terms →
Where researchers source BPC-157
For researchers studying BPC-157, third-party suppliers such as Practically Natty Peptides offer research-grade material with third-party Certificates of Analysis and US-based shipping.
View research-supplier listing →
Outbound link to a third-party research supplier. Inclusion does not constitute endorsement; all editorial content is developed independently.
Frequently asked questions
What is BPC-157 and what class of peptide is it?
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide of 15 amino acids derived from a partial sequence of a protein found in human gastric juice. It is studied in the research literature as a cytoprotective and tissue-repair agent, not as an approved drug. It has no established endogenous receptor and its mechanisms are still under active investigation.
What is BPC-157 studied for in the research literature?
In animal models, BPC-157 has been researched in the context of tendon, ligament, muscle, and bone healing, gastrointestinal mucosal protection, and angiogenesis. Much of the work implicates nitric oxide pathways and upregulation of growth-factor and angiogenic signaling. To date these findings are almost entirely preclinical, and no human clinical efficacy has been established.
Why is BPC-157's short half-life not reflected in dosing frequency?
Pharmacokinetic work in rats and dogs reports an elimination half-life under about 30 minutes, yet most rodent studies use once-daily dosing. This is often described as a PK/PD disconnect: the downstream biological effects the peptide triggers persist well beyond the peptide's own residence time. Researchers therefore design protocols around effect duration rather than plasma half-life.
How is BPC-157 typically reconstituted and stored in research settings?
BPC-157 is supplied as a lyophilized powder and is reconstituted with bacteriostatic water, added slowly down the vial wall and swirled rather than shaken to avoid degrading the peptide. Reconstituted solution is generally stored refrigerated at 2-8 C and protected from light. Lyophilized powder is more stable and is often kept frozen for longer-term storage.
Is BPC-157 an approved drug?
No. BPC-157 is not approved by the FDA or comparable regulators and is sold strictly as a research chemical. It is also prohibited in sport under WADA's S0 category for non-approved substances. All available human-relevant claims derive from preclinical models.
How does BPC-157 differ from TB-500?
Both are studied for tissue repair but differ in origin and mechanism: BPC-157 is a 15-amino-acid gastric-derived peptide associated with angiogenesis and nitric-oxide pathways, while TB-500 relates to thymosin beta-4 and actin regulation and cell migration. They are frequently co-studied because their proposed mechanisms are viewed as complementary rather than overlapping.
Answers are educational summaries of research-literature context and do not constitute medical advice. See the Research Library, COA guide, and Storage & Handling guide for more.